-
Mashup Score: 0Frontline Tislelizumab Plus Chemo Improves PFS in Recurrent/Metastatic Nasopharyngeal Cancer - 2 year(s) ago
Benefit across a range of survival end points, including progression-free survival, shown with tislelizumab and chemotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma - 3 year(s) ago
The RATIONALE 311 study is a Phase III clinical trial designed to evaluate the efficacy and safety of tislelizumab combined with concurrent CRT in patients with inoperable localized ESCC.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rong Yu et al describe the rationale and design of the ongoing Phase III RATIONALE 311 study examining tislelizumab in patients with inoperable localized ESCC. The #openaccess article can be found at the link below. 📚 - https://t.co/lpejeDeSSL #ESCC #tislelizumab
-
-
Mashup Score: 4The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable Hepatocellular Carcinoma - 3 year(s) ago
Tislelizumab showed durable responses and was well tolerated in patients who received previous systemic treatment
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The investigational PD1 antibody, #tislelizumab, shows promise in pts w/ unresectable #HepatocellularCarcinoma: Tislelizumab showed durable responses & was well tolerated in pts who received previous systemic treatment 📑 https://t.co/0y2H5oqV3m #WorldGI2021 @DucreuxMichel #HCC https://t.co/Qck6fhRKx8
-
-
Mashup Score: 0
The China National Medical Products Administration has accepted a supplemental new drug application for tislelizumab in combination with chemotherapy for the frontline treatment of patients with advanced nonsquamous non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The China National Medical Products Administration has accepted a supplemental new drug application for #tislelizumab in combination with chemotherapy for the frontline treatment of patients with advanced nonsquamous NSCLC. @ASCO #ASCO20 #lcsm https://t.co/MsQJpMHYBf
-
-
Mashup Score: 0
BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung can…
Source: U.K.Categories: Hem/OncsTweet-
Not much info here, but noteworthy: Experimental I-O cancer drug manufactured by Beijing-based company, BeiGene, meets main goal in late-stage lung cancer study, @Reuters - https://t.co/S1H4CwiNP6 #Tislelizumab is an investigational anti–PD-1 antibody https://t.co/XAcHGdE3Or
-
Benefit across a range of survival end points, including progression-free survival, shown with #tislelizumab and chemotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma. #hancsm #oncology #ASCO22 https://t.co/0BwifV1h1l